HUMAN INSULIN DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)
Human Insulin Drugs Market is likely to reach USD 32 billion by 2027 at a CAGR greater than 3% over the forecast period.
The COVID-19 pandemic has had a substantial impact on the Human Insulin Drugs Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people.
Diabetes is associated with many health complications. People with diabetes have a 300% increased risk of being hospitalized compared to those without diabetes, and thus, they incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels, so as to prevent the long-term complications associated with fluctuations in blood glucose levels, are at greater risk for overcorrection and the resultant hypoglycemia.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Key Market TrendsGrowing Diabetes Prevalence Driving the MarketAll Type 1 diabetes patients and a limited number of Type 2 diabetes patients require daily insulin injections as part of their treatment. As per the ADA, around 67.3% of the cost of diabetes care in the United States is provided by government insurance (including Medicare, Medicaid, and the military). The rest is paid for by private insurance (30.7%) or by the uninsured (2%).
In Canada, the total diabetic population in the country increased by approximately 32% between 2016-2020, and about 8% of the diabetic population has Type 1 diabetes. Many developing countries in North America, including the Caribbean countries, are undergoing an epidemiologic transition and experiencing rapid increases in the prevalence of diabetes.
As of 2021, the prevalence rates for diabetes ranged from 12% to 19% of the population in several countries in the region.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Market.
North America Dominates the MarketNorth America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region because of a sedentary lifestyle. The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself. The United States accounts for the highest sales of long-acting insulin, Lantus, across the world. Most diabetic drug manufacturing companies consider the country as a critical market for improving overall global sales. Lantus is the most administered basal insulin across the world, accounting for a dominant share in the US market. The traditional North American human insulin drugs market is expected to grow during the forecast period, due to its economic affordability to patients. Humulin holds the highest market share, followed by Novolin. There are no generic competitors for the traditional North American human insulin drugs market in the United States.
The United States accounts for the highest sales of Humalog across the world, with over 56% of the market share. The majority of the diabetes drug manufacturing companies consider the country a critical market for improving overall global sales. In the United States, Humalog is available in different varieties under names like Humalog Mix 75/25, Humalog U-100, Humalog U-200, and Humalog Mix 50/50 for the treatment of diabetes.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Human Insulin Drugs Market.
Competitive LandscapeThe global human insulin market is highly consolidated with three major manufacturers holding a global market presence, and the remaining manufacturers confined to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine). Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus, providing a more convenient, effective, as well as a safer method for delivering insulin therapy.
Additional Benefits:- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
- 1 INTRODUCTION
- 1.1 Study Assumptions
- 1.2 Scope of the Study
- 2 RESEARCH METHODOLOGY
- 3 EXECUTIVE SUMMARY
- 4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
- 5 MARKET SEGMENTATION
- 5.1 By Product Type
- 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2016 - 2027)
- 5.1.1.1 Lantus (Insulin glargine)
- 5.1.1.2 Levemir (Insulin detemir)
- 5.1.1.3 Toujeo (Insulin glargine)
- 5.1.1.4 Tresiba (Insulin degludec)
- 5.1.1.5 Basaglar (Insulin glargine)
- 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2016 - 2027)
- 5.1.2.1 NovoRapid/Novolog (Insulin aspart)
- 5.1.2.2 Humalog (Insulin lispro)
- 5.1.2.3 Apidra (Insulin glulisine)
- 5.1.2.4 FIASP (Insulin aspart)
- 5.1.2.5 Admelog (Insulin lispro)
- 5.1.3 Traditional Human Insulins (Value and Volume, 2016 - 2027)
- 5.1.3.1 Novolin/Actrapid/Insulatard
- 5.1.3.2 Humulin
- 5.1.3.3 Insuman
- 5.1.4 Combination Insulins (Value and Volume, 2016 - 2027)
- 5.1.4.1 NovoMix (Biphasic Insulin aspart)
- 5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)
- 5.1.4.3 Xultophy (Insulin degludec/Liraglutide)
- 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
- 5.1.5 Biosimilar Insulins (Value and Volume, 2016 - 2027)
- 5.1.5.1 Insulin Glargine Biosimilars
- 5.1.5.2 Human Insulin Biosimilars
- 5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States (Value and Volume, 2016 - 2027)
- 5.2.1.1.1 Basal or Long-acting Insulins
- 5.2.1.1.2 Bolus or Fast-acting Insulins
- 5.2.1.1.3 Traditional Human Insulins
- 5.2.1.1.4 Combination Insulins
- 5.2.1.1.5 Biosimilar Insulins
- 5.2.1.2 Canada (Value and Volume, 2016 - 2027)
- 5.2.1.2.1 Basal or Long-acting Insulins
- 5.2.1.2.2 Bolus or Fast-acting Insulins
- 5.2.1.2.3 Traditional Human Insulins
- 5.2.1.2.4 Combination Insulins
- 5.2.1.2.5 Biosimilar Insulins
- 5.2.1.3 Rest of North America (Value and Volume, 2016 - 2027)
- 5.2.1.3.1 Basal or Long-acting Insulins
- 5.2.1.3.2 Bolus or Fast-acting Insulins
- 5.2.1.3.3 Traditional Human Insulins
- 5.2.1.3.4 Combination Insulins
- 5.2.1.3.5 Biosimilar Insulins
- 5.2.2 Europe
- 5.2.2.1 France (Value and Volume, 2016 - 2027)
- 5.2.2.1.1 Basal or Long-acting Insulins
- 5.2.2.1.2 Bolus or Fast-acting Insulins
- 5.2.2.1.3 Traditional Human Insulins
- 5.2.2.1.4 Combination Insulins
- 5.2.2.1.5 Biosimilar Insulins
- 5.2.2.2 Germany (Value and Volume, 2016 - 2027)
- 5.2.2.2.1 Basal or Long-acting Insulins
- 5.2.2.2.2 Bolus or Fast-acting Insulins
- 5.2.2.2.3 Traditional Human Insulins
- 5.2.2.2.4 Combination Insulins
- 5.2.2.2.5 Biosimilar Insulins
- 5.2.2.3 Italy (Value and Volume, 2016 - 2027)
- 5.2.2.3.1 Basal or Long-acting Insulins
- 5.2.2.3.2 Bolus or Fast-acting Insulins
- 5.2.2.3.3 Traditional Human Insulins
- 5.2.2.3.4 Combination Insulins
- 5.2.2.3.5 Biosimilar Insulins
- 5.2.2.4 Spain (Value and Volume, 2016 - 2027)
- 5.2.2.4.1 Basal or Long-acting Insulins
- 5.2.2.4.2 Bolus or Fast-acting Insulins
- 5.2.2.4.3 Traditional Human Insulins
- 5.2.2.4.4 Combination Insulins
- 5.2.2.4.5 Biosimilar Insulins
- 5.2.2.5 United Kingdom (Value and Volume, 2016 - 2027)
- 5.2.2.5.1 Basal or Long-acting Insulins
- 5.2.2.5.2 Bolus or Fast-acting Insulins
- 5.2.2.5.3 Traditional Human Insulins
- 5.2.2.5.4 Combination Insulins
- 5.2.2.5.5 Biosimilar Insulins
- 5.2.2.6 Russia (Value and Volume, 2016 - 2027)
- 5.2.2.6.1 Basal or Long-acting Insulins
- 5.2.2.6.2 Bolus or Fast-acting Insulins
- 5.2.2.6.3 Traditional Human Insulins
- 5.2.2.6.4 Combination Insulins
- 5.2.2.6.5 Biosimilar Insulins
- 5.2.2.7 Rest of Europe (Value and Volume, 2016 - 2027)
- 5.2.2.7.1 Basal or Long-acting Insulins
- 5.2.2.7.2 Bolus or Fast-acting Insulins
- 5.2.2.7.3 Traditional Human Insulins
- 5.2.2.7.4 Combination Insulins
- 5.2.2.7.5 Biosimilar Insulins
- 5.2.3 Latin America
- 5.2.3.1 Mexico (Value and Volume, 2016 - 2027)
- 5.2.3.1.1 Basal or Long-acting Insulins
- 5.2.3.1.2 Bolus or Fast-acting Insulins
- 5.2.3.1.3 Traditional Human Insulins
- 5.2.3.1.4 Combination Insulins
- 5.2.3.1.5 Biosimilar Insulins
- 5.2.3.2 Brazil (Value and Volume, 2016 - 2027)
- 5.2.3.2.1 Basal or Long-acting Insulins
- 5.2.3.2.2 Bolus or Fast-acting Insulins
- 5.2.3.2.3 Traditional Human Insulins
- 5.2.3.2.4 Combination Insulins
- 5.2.3.2.5 Biosimilar Insulins
- 5.2.3.3 Rest of Latin America (Value and Volume, 2016 - 2027)
- 5.2.3.3.1 Basal or Long-acting Insulins
- 5.2.3.3.2 Bolus or Fast-acting Insulins
- 5.2.3.3.3 Traditional Human Insulins
- 5.2.3.3.4 Combination Insulins
- 5.2.3.3.5 Biosimilar Insulins
- 5.2.4 Asia-Pacific
- 5.2.4.1 Japan (Value and Volume, 2016 - 2027)
- 5.2.4.1.1 Basal or Long-acting Insulins
- 5.2.4.1.2 Bolus or Fast-acting Insulins
- 5.2.4.1.3 Traditional Human Insulins
- 5.2.4.1.4 Combination Insulins
- 5.2.4.1.5 Biosimilar Insulins
- 5.2.4.2 South Korea (Value and Volume, 2016 - 2027)
- 5.2.4.2.1 Basal or Long-acting Insulins
- 5.2.4.2.2 Bolus or Fast-acting Insulins
- 5.2.4.2.3 Traditional Human Insulins
- 5.2.4.2.4 Combination Insulins
- 5.2.4.2.5 Biosimilar Insulins
- 5.2.4.3 China (Value and Volume, 2016 - 2027)
- 5.2.4.3.1 Basal or Long-acting Insulins
- 5.2.4.3.2 Bolus or Fast-acting Insulins
- 5.2.4.3.3 Traditional Human Insulins
- 5.2.4.3.4 Combination Insulins
- 5.2.4.3.5 Biosimilar Insulins
- 5.2.4.4 India (Value and Volume, 2016 - 2027)
- 5.2.4.4.1 Basal or Long-acting Insulins
- 5.2.4.4.2 Bolus or Fast-acting Insulins
- 5.2.4.4.3 Traditional Human Insulins
- 5.2.4.4.4 Combination Insulins
- 5.2.4.4.5 Biosimilar Insulins
- 5.2.4.5 Australia (Value and Volume, 2016 - 2027)
- 5.2.4.5.1 Basal or Long-acting Insulins
- 5.2.4.5.2 Bolus or Fast-acting Insulins
- 5.2.4.5.3 Traditional Human Insulins
- 5.2.4.5.4 Combination Insulins
- 5.2.4.5.5 Biosimilar Insulins
- 5.2.4.6 Vietnam (Value and Volume, 2016 - 2027)
- 5.2.4.6.1 Basal or Long-acting Insulins
- 5.2.4.6.2 Bolus or Fast-acting Insulins
- 5.2.4.6.3 Traditional Human Insulins
- 5.2.4.6.4 Combination Insulins
- 5.2.4.6.5 Biosimilar Insulins
- 5.2.4.7 Malaysia (Value and Volume, 2016 - 2027)
- 5.2.4.7.1 Basal or Long-acting Insulins
- 5.2.4.7.2 Bolus or Fast-acting Insulins
- 5.2.4.7.3 Traditional Human Insulins
- 5.2.4.7.4 Combination Insulins
- 5.2.4.7.5 Biosimilar Insulins
- 5.2.4.8 Indonesia (Value and Volume, 2016 - 2027)
- 5.2.4.8.1 Basal or Long-acting Insulins
- 5.2.4.8.2 Bolus or Fast-acting Insulins
- 5.2.4.8.3 Traditional Human Insulins
- 5.2.4.8.4 Combination Insulins
- 5.2.4.8.5 Biosimilar Insulins
- 5.2.4.9 Philippines (Value and Volume, 2016 - 2027)
- 5.2.4.9.1 Basal or Long-acting Insulins
- 5.2.4.9.2 Bolus or Fast-acting Insulins
- 5.2.4.9.3 Traditional Human Insulins
- 5.2.4.9.4 Combination Insulins
- 5.2.4.9.5 Biosimilar Insulins
- 5.2.4.10 Thailand (Value and Volume, 2016 - 2027)
- 5.2.4.10.1 Basal or Long-acting Insulins
- 5.2.4.10.2 Bolus or Fast-acting Insulins
- 5.2.4.10.3 Traditional Human Insulins
- 5.2.4.10.4 Combination Insulins
- 5.2.4.10.5 Biosimilar Insulins
- 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2016 - 2027)
- 5.2.4.11.1 Basal or Long-acting Insulins
- 5.2.4.11.2 Bolus or Fast-acting Insulins
- 5.2.4.11.3 Traditional Human Insulins
- 5.2.4.11.4 Combination Insulins
- 5.2.4.11.5 Biosimilar Insulins
- 5.2.5 Middle-East and Africa
- 5.2.5.1 Saudi Arabia (Value and Volume, 2016 - 2027)
- 5.2.5.1.1 Basal or Long-acting Insulins
- 5.2.5.1.2 Bolus or Fast-acting Insulins
- 5.2.5.1.3 Traditional Human Insulins
- 5.2.5.1.4 Combination Insulins
- 5.2.5.1.5 Biosimilar Insulins
- 5.2.5.2 Iran (Value and Volume, 2016 - 2027)
- 5.2.5.2.1 Basal or Long-acting Insulins
- 5.2.5.2.2 Bolus or Fast-acting Insulins
- 5.2.5.2.3 Traditional Human Insulins
- 5.2.5.2.4 Combination Insulins
- 5.2.5.2.5 Biosimilar Insulins
- 5.2.5.3 Egypt (Value and Volume, 2016 - 2027)
- 5.2.5.3.1 Basal or Long-acting Insulins
- 5.2.5.3.2 Bolus or Fast-acting Insulins
- 5.2.5.3.3 Traditional Human Insulins
- 5.2.5.3.4 Combination Insulins
- 5.2.5.3.5 Biosimilar Insulins
- 5.2.5.4 Oman (Value and Volume, 2016 - 2027)
- 5.2.5.4.1 Basal or Long-acting Insulins
- 5.2.5.4.2 Bolus or Fast-acting Insulins
- 5.2.5.4.3 Traditional Human Insulins
- 5.2.5.4.4 Combination Insulins
- 5.2.5.4.5 Biosimilar Insulins
- 5.2.5.5 South Africa (Value and Volume, 2016 - 2027)
- 5.2.5.5.1 Basal or Long-acting Insulins
- 5.2.5.5.2 Bolus or Fast-acting Insulins
- 5.2.5.5.3 Traditional Human Insulins
- 5.2.5.5.4 Combination Insulins
- 5.2.5.5.5 Biosimilar Insulins
- 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2016 - 2027)
- 5.2.5.6.1 Basal or Long-acting Insulins
- 5.2.5.6.2 Bolus or Fast-acting Insulins
- 5.2.5.6.3 Traditional Human Insulins
- 5.2.5.6.4 Combination Insulins
- 5.2.5.6.5 Biosimilar Insulins
- 6 MARKET INDICATORS
- 6.1 Type 1 Diabetes Population (2016 - 2027)
- 6.2 Type 2 Diabetes Population (2016 - 2027)
- 7 COMPETITIVE LANDSCAPE
- 7.1 COMPANY PROFILES
- 7.1.1 Novo Nordisk A/S
- 7.1.1.1 Overview
- 7.1.1.2 Products and Strategies
- 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
- 7.1.1.4 Ratio Analysis (5 Years)
- 7.1.1.5 Strength and Stability Analysis (5 Years)
- 7.1.1.6 Recent Developments
- 7.1.2 Sanofi S.A.
- 7.1.2.1 Overview
- 7.1.2.2 Products and Strategies
- 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
- 7.1.2.4 Ratio Analysis (5 Years)
- 7.1.2.5 Strength and Stability Analysis (5 Years)
- 7.1.2.6 Recent Developments
- 7.1.3 Eli Lilly and Company
- 7.1.3.1 Overview
- 7.1.3.2 Products and Strategies
- 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
- 7.1.3.4 Ratio Analysis (5 Years)
- 7.1.3.5 Strength and Stability Analysis (5 Years)
- 7.1.3.6 Recent Developments
- 7.1.4 Biocon Limited
- 7.1.4.1 Overview
- 7.1.4.2 Products and Strategies
- 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
- 7.1.4.4 Ratio Analysis (5 Years)
- 7.1.4.5 Strength and Stability Analysis (5 Years)
- 7.1.4.6 Recent Developments
- 7.1.5 Pfizer Inc.
- 7.1.5.1 Overview
- 7.1.5.2 Products and Strategies
- 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
- 7.1.5.4 Ratio Analysis (5 Years)
- 7.1.5.5 Strength and Stability Analysis (5 Years)
- 7.1.5.6 Recent Developments
- 7.1.6 Wockhardt
- 7.1.6.1 Overview
- 7.1.6.2 Products and Strategies
- 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
- 7.1.6.4 Ratio Analysis (5 Years)
- 7.1.6.5 Strength and Stability Analysis (5 Years)
- 7.1.6.6 Recent Developments
- 7.1.7 Julphar
- 7.1.7.1 Overview
- 7.1.7.2 Products and Strategies
- 7.1.7.3 Recent Developments
- 7.1.8 Exir
- 7.1.8.1 Overview
- 7.1.8.2 Products and Strategies
- 7.1.8.3 Recent Developments
- 7.1.9 Sedico
- 7.1.9.1 Overview
- 7.1.9.2 Products and Strategies
- 7.1.9.3 Recent Developments
- 7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Novo Nordisk AS
- 7.2.2 Sanofi Aventis
- 7.2.3 Eli Lilly
- 7.2.4 Other Companies
- 8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook